Results 51 to 60 of about 7,958,059 (273)

IL-17 and -23 Inhibitors for the Treatment of Psoriasis

European Medical Journal Allergy & Immunology, 2023
Psoriasis is a chronic inflammatory skin condition with a significant global burden of disease and a wide array of potential treatment options, ranging from topical to systemic therapies. There are currently 11 biologic agents approved by the U.S.
Sonali Batta, Ramlah Khan, Marcus Zaayman, Allison Limmer, Dario Kivelevitch, Alan Menter   +5 more
doaj   +1 more source

Association Between Individualized Education for Kidney Replacement Therapy Modality Selection and Peritoneal Dialysis Initiation: A Cross‐Sectional Study

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Introduction Peritoneal dialysis (PD) is an established home‐based kidney replacement therapy (KRT), but its uptake remains low in Japan. We evaluated whether individualized education in a dedicated outpatient clinic was associated with the initiation of PD.
Yasuko Ito, Ryuichi Yoshimura, Takaki Yamauchi, Yuta Funakoshi, Hirotaka Sonoda, Seiji Kobayashi, Hiroyuki Terawaki, Takafumi Ito   +7 more
wiley   +1 more source

A Review of Interleukin-23/Interleukin-17 Inhibitor Exposure during Pregnancy in Patients with Psoriasis

Clinical Dermatology Review
Psoriasis is an immune cell-mediated chronic relapsing inflammatory skin disease that often develops during the reproductive years of women. The treatment of psoriasis during pregnancy is challenging as remarkable changes occur in the maternal body, and ...
Nirali Doshi, Bijal Prajapati, Lavanya Selvaraj   +2 more
doaj   +1 more source

Enteropathogenic E. coli shows delayed attachment and host response in human jejunum organoid‐derived monolayers compared to HeLa cells

FEBS Letters, EarlyView.
Enteropathogenic E. coli (EPEC) infects the human intestinal epithelium, resulting in severe illness and diarrhoea. In this study, we compared the infection of cancer‐derived cell lines with human organoid‐derived models of the small intestine. We observed a delayed in attachment, inflammation and cell death on primary cells, indicating that host ...
Mastura Neyazi, Pilar Samperio Ventayol, Natalie Burkard, Nicolas Schlegel, Carmen Aguilar, Sina Bartfeld   +5 more
wiley   +1 more source

IL-23 Inhibitors for Moderate-to-Severe Plaque Psoriasis: A Review of Clinical Efficacy, Safety, and Tolerability

European Medical Journal Dermatology, 2019
Psoriasis is a chronic, immune-mediated skin condition with systemic involvement, frequently requiring long-term treatment. At present, there are 11 biologic agents available for the treatment of moderate-to-severe psoriasis, which target specific ...
Sima D. Amin, Annika S. Silfvast-Kaiser, So Yeon Paek, Dario Kivelevitch, Alan Menter   +4 more
doaj  

IL-23-induced IL-17 production by activated human T cells in a dose-dependent manner

, 2011
Copyright information:Taken from "IL-23 induces human osteoclastogenesis via IL-17 , and anti-IL-23 antibody attenuates collagen-induced arthritis in rats"http://arthritis-research.com/content/9/5/R96Arthritis Research & Therapy 2007;9(5):R96-R96 ...
Manabu Kawamoto (18939), Yuki Nanke (39152), Shigeru Kotake (935), Takefumi Furuya (39153), Toru Yago (39151), Tsuyoshi Kobashigawa (39154), Naoyuki Kamatani (936)   +6 more
core   +1 more source

The planar cell polarity protein Vangl2 interacts with the PDZ‐domains of Scribble but not with a unique PDZ‐like domain in Inturned

FEBS Letters, EarlyView.
Structural and biochemical characterisations show that the planar cell polarity (PCP) protein Inturned harbours a unique PDZ‐like domain that does not bind canonical PDZ‐binding motifs (PBMs) like that of another PCP protein Vangl2. In contrast, the apical‐basal polarity protein Scribble contains four PDZ domains that bind Vangl2, but one PDZ domain ...
Stephan Wilmes, Jan Brysch, Carmen Gelze, Lilli Meier, Daniel Kümmel   +4 more
wiley   +1 more source

Interleukin-23 inhibitors

, 2022
For adult patients with moderate to severe plaque psoriasis scheduled for systemic therapy, FDA-approved agents that act via interleukin-23 (IL-23) inhibition are guselkumab, tildrakizumab, and risankizumab.
Adisen, Esra
core   +1 more source

Interleukin-17 vs. Interleukin-23 Inhibitors in Pustular and Erythrodermic Psoriasis: A Retrospective, Multicentre Cohort Study [PDF]

, 2023
Pustular and erythrodermic psoriasis are rare and difficult-to-treat conditions. It has recently been shown that interleukin (IL)-17 inhibitors can be very effective among patients with these forms of psoriasis; however, the potential of IL-23 inhibitors
Luca Mastorino, Carrera, Carlo Giovanni, Gianluca Avallone, Paolo Dapavo, Ribero, Simone, Mastorino, Luca, Dapavo, Paolo, Maronese, Carlo Alberto, Marzano, Angelo Valerio, Carlo Alberto Maronese, Giulia Murgia, Gabriele Roccuzzo, Pietro Quaglino, Simone Ribero, Carlo Giovanni Carrera, Angelo Valerio Marzano, Avallone, Gianluca, Silvia Alberti-Violetti, Murgia, Giulia, Quaglino, Pietro, Roccuzzo, Gabriele, Alberti-Violetti, Silvia   +21 more
core   +1 more source

Structural insights into an engineered feruloyl esterase with improved MHET degrading properties

FEBS Letters, EarlyView.
A feruloyl esterase was engineered to mimic key features of MHETase, enhancing the degradation of PET oligomers. Structural and computational analysis reveal how a point mutation stabilizes the active site and reshapes the binding cleft, expading substrate scope.
Panagiota Karampa, Konstantinos Makryniotis, Theofani‐Iosifina Sousani, Evangelos Topakas, Vangelis Daskalakis, Maria Dimarogona   +5 more
wiley   +1 more source